Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Samukawa, T. Hamada, G. Tsukuya, H. Inoue (Kagoshima, Japan). Serum napsin A is a novel diagnostic and monitoring marker for interstitial lung disease. Eur Respir J 2011; 38: Suppl. 55, 4774

Member's Comments

No comment yet.

Related content which might interest you: KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Human napsin a is a useful serum marker of interstitial lung disease, compared to KL-6, and surfactant protein-D Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay. Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Elevation of serum tumor markers in patients with interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 KL-6 as a potential therapeutic biomarker in fibrosing interstitial lung diseases Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Serum HSP47 is a novel blood marker for rapidly progressive interstitial pneumonia Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Serum napsin A as a tumor marker for primary lung adenocarcinoma Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease. Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020 Year: 2020 alpha-v-beta-6 integrin may be a potential prognostic biomarker in interstitial lung disease Source: Eur Respir J 2015; 46: 486-494 Year: 2015 Usefulness of serum bird specific antibody levels in patients with interstitial pneumonia Source: International Congress 2016 – Orphan diseases II Year: 2016 Elevation of serum napsin A levels in patients with hypersensitive pneumonia Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis Source: International Congress 2016 – Connective tissue disorders Year: 2016 Serum neuron-specific enolase - a marker for disease extent and response to therapy of small-cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Serum endostatin is a novel marker for COPD associated to lung function decline and exacerbation Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016 Hyaluronan: A novel sputum marker for the screening and diagnosis of lung cancer patients Source: Annual Congress 2012 - Early detection of lung cancer Year: 2012 Increased cytokeratin-19 expression in fibrotic interstitial lung disease Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010